No, Miniscalpel-Needle (MSN) Treatment is NOT the Same as Trigger Point Injections
MSN and trigger point injections are distinct interventional techniques that differ fundamentally in their mechanism, instrumentation, and clinical application, though both target myofascial pain.
Key Differences Between MSN and Trigger Point Injections
Instrumentation and Technique
Miniscalpel-needle (MSN) is a specialized instrument developed in China that combines features of both an acupuncture needle and a surgical scalpel 1, 2, 3. It performs a "release" technique that mechanically disrupts adhesions and tight fascial bands in myofascial tissues. The MSN is designed to cut or release tissue structures rather than simply puncture them.
Trigger point injections (TPI), in contrast, involve inserting a standard hypodermic needle into myofascial trigger points with the primary goal of either mechanical disruption (dry needling) or delivering therapeutic substances such as local anesthetics, corticosteroids, or botulinum toxin 4, 5. The needle itself is not designed for tissue cutting or release.
Mechanism of Action
- MSN: Works through mechanical release of fascial adhesions and tight tissue bands, creating a more substantial tissue disruption than simple needling 1, 2
- TPI: Achieves effects through mechanical disruption of trigger points (if dry needling) or through pharmacological action of injected substances combined with mechanical disruption 4, 5
Clinical Evidence and Outcomes
The research evidence demonstrates different efficacy profiles:
MSN shows sustained long-term benefits: Studies comparing MSN to other interventions demonstrate sustained improvements at 6-12 months. For chronic neck pain, MSN provided superior pain reduction compared to dry needling at both 3 months (2-point VAS improvement) and 6 months (0.9-point improvement) 1. For plantar fasciitis, MSN showed sustained benefits at 12 months while steroid injection effects diminished after 1 month 2.
Trigger point injections show variable evidence: The evidence for TPI is mixed and generally shows short-term benefits. Multiple randomized trials found that the effect of trigger point injections was independent of the injected substance, suggesting the needle itself (not the medication) provides the therapeutic benefit 4, 6. A 2022 meta-analysis found TPI (wet needling) superior to dry needling for short-term pain reduction but found no differences in disability, pressure pain thresholds, or cervical mobility 7.
Clinical Practice Implications
When to Consider Each Technique
Consider MSN for:
- Chronic myofascial pain requiring sustained relief (>6 months)
- Conditions involving fascial adhesions or tissue restrictions
- Patients who have failed conventional trigger point injections
- Plantar fasciitis, chronic neck pain, or trigger thumb where evidence supports its use 1, 8, 2
Consider Trigger Point Injections for:
- Acute myofascial pain syndromes
- Initial conservative management attempts
- When pharmacological adjuncts (local anesthetics, steroids) may provide additional benefit
- Settings where MSN expertise is unavailable
Important Caveats
Guideline recommendations for trigger point injections are contradictory: The 2022 American Society of Pain and Neuroscience guidelines provide a "strong recommendation in favour of trigger point injections" for chronic back pain 9, while the 2021 American College of Occupational and Environmental Medicine guidelines recommend TPI "only for chronic low back pain not resolving with exercise or NSAIDs" and specifically recommend against glucocorticosteroids 9. The 2025 BMJ guideline notes that "several clinical practice guidelines for interventional procedures are characterised as consensus based" and "more likely to produce recommendations that violate the principles of evidence based medicine" 9.
Evidence quality concerns: A 2001 systematic review concluded that "no trials were of sufficient quality or design to test the efficacy of any needling technique beyond placebo" and that "any effect of these therapies is likely because of the needle or placebo rather than the injection" 6. This fundamental limitation affects interpretation of all needling therapies.
MSN requires specialized training: MSN is not widely practiced outside of China and requires specific technical expertise that differs from standard trigger point injection technique 1, 2, 3.
Safety Profile
Both techniques demonstrate acceptable safety profiles with no severe complications reported in comparative trials 1, 2. However, trigger point injections carry small risks of infection, temporary altered consciousness, and very rare catastrophic complications including paralysis when performed near the spine 9.
In summary: While both techniques involve needling myofascial tissues, MSN represents a distinct mechanical release procedure with evidence for sustained long-term benefits, whereas trigger point injections represent a broader category of interventions with more variable and typically shorter-term effects. They should not be considered interchangeable techniques.